- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W -

- Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg -

- Grade 3 diarrhea rate of 10% in ongoing dose optimization cohorts -

- FDA interactions targeted for mid-year with goal to align on potential registrational trial design in late-line colorectal cancer (CRC) -

- Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 -

- Conference call on Monday, March 16 at 8:00 a.m. ET -

SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced positive Phase 1 expansion data for its EpCAM PROBODY® ADC, varsetatug masetecan (Varseta-M) in late-line metastatic CRC. The preliminary data are as of a January 16, 2026 data cutoff from the ongoing CTMX-2051-101 Phase 1 study.